Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer

Phillips, Andrew; Balega, Janos; Nevin, James; Singh, Kavita; Elattar, Ahmed; Kehoe, Sean; Sundar, Sudha

Link to publication on Research at Birmingham portal

1   Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian

2   cancer

3

4   Andrew Phillips MB ChB BSc MA MRCOG[1]

5   Janos Balega MD MRCOG[1]

6   James Nevin MBBCh MRCOG FROG[1]

7   Kavita Singh MBBS MD FRCOG[1]

8   Ahmed Elattar MD MRCOG[1]

9   Sean Kehoe MD MA DCH MRCOG[1, 2]

10   Sudha Sundar MBBS MPhil MRCOG[1, 2]

11   [1]Pan-Birmingham Gynaecological Cancer Centre, City Hospital, Dudley Rd, Birmingham

12   B18 7QH, United Kingdom

13   [2] Institute of Cancer and Genomic Sciences, Vincent Drive, University of Birmingham,

14   Birmingham, B15 2TT, United Kingdom

15

16

17

18   Corresponding Author:

19   Sudha Sundar

20   Pan-Birmingham Gynaecological Cancer Centre, City Hospital, Dudley Rd, Birmingham B18

21   7QH, United Kingdom

22   Email: s.s.sundar@bham.ac.uk

23   Telephone +44 121 414 5075337

24

25

26

ABSTRACT

Objective

Combined surgery and platinum-based chemotherapy is the internationally agreed standard therapy for advanced ovarian cancer (AOC). However international cancer registry datasets demonstrate a significant proportion of patients do not receive both or either therapies. Our objective was to evaluate the effect of total patient cohort data ('Denominator') on median overall survival (OS) and determine how frequently this was reported in literature.

Methods

We retrospectively reviewed OS outcomes for 593 patients diagnosed with AOC for 77 months at a regional cancer centre. Patients were stratified into five progressively overlapping categories based on treatment received - Primary debulking surgery (PDS), PDS or Interval debulking (IDS), all surgery and those considered for IDS, patients receiving any treatment and total patient cohort. A systematic search of literature was performed.

Results

Median OS progressively decreased from 54.5 months in patients receiving PDS, 38.7 months in the PDS +IDS group, 35.4 months in the PDS/IDS + patients considered for IDS, 33.3 months in patients receiving any treatment and 30.2 months in the total patient cohort. OS in the surgically treated group was statistically significantly different from the OS in the total patient cohort (Denominator)(p=0.000353). Denominator descriptors were identified in 11% of studies.

Conclusions

Denominator data is critical to understanding selection and OS in AOC. Published outcomes of selected cohorts should routinely incorporate outcomes for all women managed within the reporting Centre. This is essential for benchmarking and quality assurance in gynaecological cancer and should be an integral part of any publication on outcomes from AOC.

61 KEYWORDS

62 Ovarian cancer; Denominator; Survival; Surgery; Chemotherapy; Patient selection

INTRODUCTION

Disease burden with cytoreductive outcomes following debulking surgery and platinum sensitivity are two of the strongest predictors of survival in advanced ovarian cancer (AOC)[1-3]. As such, the importance of surgery is reflected in published international guidelines[4, 5]. However, both the United States SEER data and the United Kingdom Cancer registry datasets demonstrate that up to 44% of patients with AOC do not receive optimum therapy[6, 7]. Explanations for such deviations in care include: elderly patients; emergency presentations; unclear histology; significant co-morbidities; as well as patient choice[7-9]. Investigating the underlying factors for this under-treated group has been difficult with limited data recorded in national databases in these patients compared to their counterparts who receive treatment[9].

In contrast, there are numerous publications, mainly single centre based, on the success associated with primary cytoreductive surgery where attempted[10-16]. In this latter group, survival data is often presented without reference to the population from which they are derived. This makes it impossible to ascertain the selection processes which resulted in the reported patient cohort. Patient selection in AOC between centres can vary by: i) by the proportion of patients selected at each centre to receive any treatment; ii) those managed by primary surgery vs neoadjuvant chemotherapy and; iii) finally by the proportion who following neoadjuvant chemotherapy have debulking surgery. All of these variables may render the population reported showing an excellent outcome (e.g. by selecting only those with a high chance of complete cytoreduction) or a poorer outcome (by a policy that all patients are exposed to primary surgery). Failure to report the proportion of patients receiving each treatment modality therefore risks bias, with centres that routinely operate on patients with more disseminated disease potentially reporting inferior survival data in their surgical arm compared to centres that would routinely manage similar patients with the same tumour load with chemotherapy or palliation. The more aggressive centres may however have superior overall survival (OS) data because they are operating on a greater proportion of patients. We define the denominator as the total number of advanced ovarian cancer cases presenting referred to a specific cancer centre or within the catchment area of a cancer centre and describe the survival shift as the 'denominator effect'.

96   In this study, we evaluate the effect of the denominator on the survival of the total AOC cases

97   in a systematic literature search of published literature and data from our cancer centre.

98

99

100   Methods

101

102   We undertook a retrospective review of all patients diagnosed with stage 3 or 4 AOC

103   between 16th August 2007 and 3rd February 2014. All patients were managed by subspecialty

104   trained gynaecological oncologists at the Pan-Birmingham Gynaecological Cancer Centre

105   (PBGCC), Birmingham, United Kingdom, which serves a population of 2.2 million people.

106   All patients were discussed at the Centre Multi-disciplinary team meeting (MDT) and

107   prospectively recorded in an electronic database. The UK system of healthcare necessitates

108   the management of every ovarian cancer patient within this population to be discussed at the

109   PBGCC MDT. Approval for this study was obtained from the hospital clinical effectiveness

110   department.

111

112   All consecutive patients diagnosed with stage 3 or 4 epithelial ovarian, tubal or peritoneal

113   cancer were identified from the database, along with those lacking a histological confirmation

114   but diagnosed based on imaging and biochemical findings and agreed as AOC by the MDT.

115   All women with suspected AOC underwent a clinical examination, transvaginal ultrasound

116   scan, serum CA125 assay and CT scan of the thorax, abdomen and pelvis, with imaging

117   reviewed by specialist gynaecological cancer radiologists. Following discussion at the MDT

118   meeting, women either underwent: primary debulking surgery (PDS), 3-4 cycles carboplatin

119   AUC 6 +/- paclitaxel 175mg/m^2 based neoadjuvant chemotherapy (NACT) with an intention

120   to consider interval debulking surgery (IDS), or palliation of symptoms alone (no

121   cytoreductive surgery or chemotherapy). Our standard approach to advanced ovarian cancer

122   is PDS followed by 6 cycles of platinum based adjuvant chemotherapy. However, patients

123   with stage 4 disease, poor performance status (ECOG/WHO 3-4), obvious porta hepatis

124   involvement on scan, small bowel mesenteric or extensive serosal involvement on diagnostic

125   laparoscopy, or with large amount of ascites/pleural effusions with low albumin level are

126   offered 3 cycles of platinum based NACT to enhance their feasibility to radical surgery with

127   3 - 5 further cycles of adjuvant chemotherapy. This is in-keeping with international

128   guidelines of practice(17, 18). Contraindications for IDS consist of progressive disease on

129   NACT, worsening performance status, severe cardiovascular disease and patient choice. All

130   patients with a response on CT/CA125 or clinical indicators are considered for IDS. The

131   PBGCC was an early adopter of advanced upper abdominal surgical procedures in the UK

132   with complete (R0) and optimal (<1cm) (R1) cytoreduction rates of 62.2% and 14.3%

133   respectively in AOC. Detailed surgical outcomes have been previously published(19).

134   Gynaecological cancer care in the UK National Health Service (NHS) is delivered at

135   designated regional cancer centres that are responsible for the care of all women with

136   gynaecological malignances within a specific catchment population. For illustration, the

137   PBGCC manages all patients with gynaecological cancer within a 2.2 million catchment

138   population. Although patient-initiated referrals to other providers are achievable, the NHS

139   system focuses referrals to named providers within a gynaecological cancer centre. Referrals

140   for private care are relatively uncommon and still necessitate discussion at, and notification

141   to, the MDT of the regional cancer centre. Referrals to other cancer centres are uncommon

142   and usually occur when a specific second opinion is required often after initial treatment has

143   been implemented. As such, within the UK NHS all women with ovarian cancer within a

144   designated region are likely to be registered with a specified cancer centre.

145   The following data were analysed: age; performance status (PS); age-adjusted Charleston co-

146   morbidity index (ACCI); Deprivation score (LSOA)(20); stage; organ of origin; histology;

147   treatment received; cytoreduction rate; surgical complexity score (SCS)(12); and survival

148   data. We classified our total patient cohort by mode of treatment received into five

149   progressively overlapping groups: group A comprised patients who underwent PDS; group B

150   comprised patients in group A and also included all patients who underwent IDS; group C

151   comprised patients in group B and also included patients who underwent assessment for IDS

152   but who did not eventually undergo surgery; group D included patients in group C and also

153   included all patients treated with chemotherapy alone; and group E included all patients in

154   group D and also included all patients who did not receive any treatment. Group E therefore

155   represents the total patient cohort 'denominator' and consists of all patients managed by our

156   cancer centre. These groups are illustrated in Figure 1. We investigated whether survival and

157   other variables differed between these five groups.

158   We performed a systematic search of EMBASE databases between 1996 to Week 03 2017

159   using a combination of text words "ovarian ca*" and Medical Subject Headings "surgery" or

160   "ovary cancer" to generate a subset of citations relevant to the research question. Search was

limited to studies involving human subjects, published in the English language, between 1.1.16 and 31.12.16. Duplicate papers were removed, as were commentaries, narrative reviews and letters. Additional papers were identified from reference lists and previously identified studies. Inclusion criteria consisted of: prospective or retrospective, single centre, cohort studies of surgically treated stage 3-4 AOC that presented OS data. Exclusion criteria consisted of: multicentre studies, randomised controlled trials of chemotherapy or papers where OS data could not be extracted. Papers were selected from their abstracts by one author (AP) with a second review by another (SS) where inclusion or exclusion was unclear. The EMBASE database was last interrogated on 18/1/17.

Statistical Analysis

Categorical variables were compared with the chi-squared test and parametric and non-parametric continuous variables were compared with the ANOVA or Kruskal-Wallis test respectively. All tests were two-sided and a p-value of less than 0.05 was regarded as being statistically significant. All tests were two-sided and a p-value of less than 0.05 was regarded as statistically significant. The Kaplan-Meier method was used to estimate survival with survival compared using the Log rank method with IBM SPSS version 20.

Results

Between 16th August 2007 and 3rd February 2014, 593 women diagnosed with advanced ovarian cancer (AOC) were identified from the database. Of these, 441 (74.4%) patients received either PDS (n=146) or IDS after NACT (n=295), and 152 (25.6%) patients received no cytoreductive surgery. The clinico-pathological data comparing those that did and did not undergo surgery is summarised in Table 1. Patients who did not undergo surgery were significantly older (p<0.00001), had a worse performance status (p<0.00001), a higher ACCI (p<0.00001), lived in more deprived regions (p<0.00001), presented with more advanced disease (p=0.0001) and were more likely not to have a histological diagnosis of their malignancy (p<0.00001).

193 Figure 1 summarises study population by treatment received. Of the 152 patients that did not

194 receive any cytoreductive surgery, 25 were considered for palliation of symptoms only due to

195 poor performance status that precluded any cancer treatment either with chemotherapy or

196 cytoreductive surgery. NACT was recommended for 123 patients but only commenced in

197 104 patients due to 14 patients dying prior to NACT and five patients declining NACT.

198 Thirteen patients did not complete all their NACT cycles due to either death or intolerance.

199 The remaining 91 patients completed all their planned NACT cycles and were subsequently

200 considered for IDS (but did not receive it). Failure to receive IDS was most commonly due

201 to: poor performance status or co-morbidities (n= 30); progressive disease following NACT

202 (n=24); no response to NACT (n=21); patient refusal of IDS (n=7); issues pertaining to

203 disease distribution (n=7); dying prior to IDS (n=1); or, unknown (n=1).

204

205 Patients who did not receive cytoreductive surgery were considered in three groups: (1) all

206 those who did not receive cytoreductive surgery (n=152); (2) those who were fit enough to

207 undergo NACT (but did not necessarily receive it) (n=123); and (3) those who completed

208 NACT and were considered for IDS (but did not undergo it) (n=91). The median OS of

209 patients in group 1 was 11.3 months (95% CI 7.8-15.0). The corresponding value for patients

210 in group 2 and 3 were 14.0 (95% CI 10.2-17.7) and 19.1 (95% CI 15.8-22.5) months

211 respectively.

212

213 Five of the 123 patients that were fit enough to undergo NACT declined chemotherapy.

214 Seven of the 91 patients that completed NACT and were considered for IDS declined

215 surgery. The median OS for the former group of patients was 6.1 months (95% CI 0.9-11.4)

216 whilst those patients in the latter group had not reached median OS by 33 months of follow

217 up.

218

219 To illustrate the 'denominator effect', we analysed the median OS for the five groups of

220 patients as described in Methods. OS progressively decreased from Group A patients (n=140)

221 with the median OS 54.5 (35.7 – 73.3) months, Group B (n=441) with median OS 38.7 (34.9

222 – 42.4) months,   Group C (n= 532) with median OS 35.4 (31.9 – 38.8) months, Group D

223 (n=564) with median OS 33.3 (29.8 – 36.8) months and Group E, the total patient cohort

224 'Denominator' with AOC (n=593 with median OS of 30.2 (26.7 – 32.6) months (Table 2)

225

226   Comparison of median OS between Group A (patients receiving PDS) and Group E (the total

227   patient cohort) demonstrated a highly statistically significant difference, p= 0.000586. There

228   was a statistically significant difference between OS in Groups B and Group E, p = 0.000353

229   and between Groups C and E, p = 0.039180. (Table 2 and Figure 2).

230

231   Eighteen studies met the specified inclusion criteria(21-38) for the systematic search. Only

232   two (11%) papers explicitly defined their total patient cohort(21, 27). Two additional papers

233   (11%) used terms which were ambiguous in relation to the total patient population(34, 35).

234   No papers presented OS for the total patient cohort although one(21) did include non-

235   operated patients with their surgical study cohort. Two papers (11%) documented the number

236   of patients who received any therapeutic treatment(21, 27) with two papers (11%) ambiguous

237   in their descriptions(34, 35). Although twelve papers (67%) explicitly described all patients

238   receiving surgery(21, 23-25, 27-30, 32, 34-36) only four papers (22.2%) published their OS

239   of all surgically managed patients(24, 28-30). Table 3 presents this and any comment on

240   survival data.

241

242   **Discussion**

243

244   In this study, we highlight the effect of the denominator on survival using our centre survival

245   data and the sparse description of denominators in published literature in AOC. To our

246   knowledge, this is the first study to explicitly define the denominator in AOC and describe its

247   relevance. Our study, demonstrates a significant difference in OS based on the total patient

248   cohort 'denominator'. Presenting denominator data would improve the understanding of the

249   process of patient selection within any given Centre, standardise selection between centres

250   and facilitate reducing selection bias which is inevitable in retrospective studies. Importantly

251   it would also help in understanding the underlying factors that preclude patients from

252   receiving therapy, thus potentially improving outcomes. OS for AOC internationally

253   continues to be poor with a five year survival of 30%(39). Unless we focus our efforts on

254   understanding the whole patient cohort of ovarian cancer, including those that do not receive

255   any treatment, obtaining improvements in OS will remain challenging.

256

257   In our series, 25.6% of patients with AOC did not receive cytoreductive surgery, 4.9% of

258   whom were too ill to receive any treatment beyond that of palliation (Figure 1). Such findings

259   are consistent with the UKs National Cancer Data Repository which has on record that 44%

260 of patients diagnosed with AOC in the UK do not receive cytoreductive surgery and 25% do

261 not receive any treatment beyond palliation(7). Such a high prevalence of undertreated

262 patients is not unique to the UK with comparable corresponding figures from the American

263 National Cancer Database (no surgery in 21% and no chemotherapy in 8.7%) and

264 Surveillance, Epidemiology and End Results (SEER) Database (no surgery in 34.2% and no

265 chemotherapy in 16.5%)(8, 9).

266

267 Whilst this manuscript demonstrated the impact on survival based on the category of patient

268 investigated, it is reasonable to expect that this denominator effect would impact as well on

269 morbidity of treatment and quality of life post treatment(40). An explicitly defined

270 denominator is crucial to efforts to benchmark survival between centres worldwide. The

271 European Society of Gynaecological Oncology should be applauded for incorporating total

272 denominator data into their recent quality standards for ovarian cancer(41). Such data can be

273 used for self-assessment, for institutional quality assurance programs, for governmental

274 quality assessment and eventually to build a network of certified centres for ovarian cancer

275 surgery that are transparent about the quality of care they deliver and the survival data that

276 their approach achieves.

277

278 Unfortunately, such robust reporting is scant in the literature and potentially artificially

279 inflates survival outcomes. Our data represents every single patient with AOC based on

280 histology, cytology and/or radiology and tumour markers in a centre serving a population of

281 2.2 million. Patients in other health care systems may be triaged in different ways. It is likely

282 that there will be variation in overall operating rates in nationalised healthcare systems

283 compared to systems with significant patient and provider selection. The total patient

284 denominator, may aid identification of those centres with an unselected patient cohort

285 compared to those treating a predominantly triaged population with good fitness for surgery.

286 The lack of total denominator data makes a fallacy of a centre's "cytoreduction rate" or

287 "primary surgery rate".

288

289 The importance of the total patient denominator has been established in numerous nationwide

290 cancer audits in the United Kingdom, such as the "National Bowel Cancer Audit Report"(42)

291 and the "National Oesophago-Gastric Cancer Audit"(43). Such basic data has allowed trends

292 in patients receiving treatment to be followed at a local, regional and national level. Both

293 these registers collect data in not only those who receive surgery but also those that, either

294   due to patient or disease factors, do not. The importance of denominator data for ovarian

295   cancer should be considered no different to these other high risk and aggressive cancers.

296

297   Even with the use of a denominator as simplistic as the total patient cohort there are still areas

298   of contention. Firstly, is the issue of AOC being defined as stage 3 or 4 disease. It is possible

299   that the true overall patient denominator may be underestimated in cases with inadequate

300   retroperitoneal or extra-pelvic exploration performed. Equally, diagnosis based on radiology

301   and tumour markers alone may increase the denominator with non-ovarian tumours

302   mimicking that of epithelial ovarian tubal and primary peritoneal cancers. The result of this

303   being that centres with suboptimal staging practice or who are less aggressive in obtaining

304   histological diagnosis are potentially going to present a cohort with inferior OS relative to

305   their peers. A potential solution would be to expand the denominator to include all stage

306   distributions of patients with ovarian cancer and to declare the proportion who did not receive

307   a histological diagnosis. The development of an outcomes "dataset" is beyond the remit of

308   this paper but standardised reporting of denominator, stage, histological diagnosis as well as

309   patient and disease descriptors would, we believe, be a tool to accurately categorise centres

310   and allow greater interpretation of centres outcomes. The development of a "core outcome"

311   set for ovarian cancer, as recommended by the COMET initiative would be a welcome

312   development in this space(44, 45). Comparisons could then be made with centres with similar

313   data distributions and thus allow their research findings to be appropriately implemented

314   either more cautiously in centres with wider but more heterogenous patient group or more

315   rapidly in similar centres.

316

317   As an important initial step, we suggest that to enable accurate interpretation of prospective

318   or retrospective cohort surgical studies in AOC, the minimum denominator descriptors that

319   should be provided should include the total number of patients as well as the total number of

320   patients operated on. Indeed, the absence of such denominator data risks a disservice to

321   studies that are innovative in their conclusions.

322

323   In conclusion, the denominator of advanced cancer cases in each centre is critical to

324   understanding selection and survival. This is essential for benchmarking and quality

325   assurance in gynaecological cancer and should be an integral part of any publication on

326   outcomes from AOC.

327

328

329   Tables/Figures

330

331   Table 1: Clinicopathological data of the total patient cohort presented comparing patients

332   who did not undergo surgery with those who underwent surgical management of AOC

333   Figure 1: Flowchart demonstrating patient outcomes for the total patient cohort

334   'denominator'.

335   Table 2: Impact on median OS by group of patients analysed demonstrating the

336   'Denominator effect'.

337   Figure 2: Kaplan-Meier curve comparing OS by patient groups A-E.

338   Table 3: Reporting of denominator data, surgical cohort data and survival data in included

339   studies

340

341

342   **Conflict of interest statement**

343

344   The authors declare no conflicts of interest

345

346   **References**

347

348   1.   Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does
349   aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex
350   surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. Journal of clinical
351   oncology : official journal of the American Society of Clinical Oncology. 2015;33(8):937-43.
352   2.   du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical
353   outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis
354   of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft
355   Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
356   d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer.
357   2009;115(6):1234-44.
358   3.   Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line
359   platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of clinical
360   oncology : official journal of the American Society of Clinical Oncology. 1991;9(3):389-93.
361   4.   Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al.
362   Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for
363   diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for
364   Medical Oncology / ESMO. 2013;24 Suppl 6:vi24-32.
365   5.   Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al.
366   Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of
367   Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
368   Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
369   2016;34(28):3460-73.

370   6.   Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Ovarian cancer outcomes:
371   Predictors of early death. Gynecologic oncology. 2016;140(3):474-80.
372   7.   Barclay M, Gildea C, Poole J, Hirschowitz L, Menon U, Nordin A. Factors Affecting Short-
373   term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based
374   Cohort Analysis of English National Cancer Registration Data. International journal of gynecological
375   cancer : official journal of the International Gynecological Cancer Society. 2016;26(1):56-65.
376   8.   Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of
377   advanced epithelial ovarian cancer in the Medicare population. Gynecologic oncology.
378   2011;122(1):100-6.
379   9.   Shalowitz DI, Epstein AJ, Ko EM, Giuntoli RL, 2nd. Non-surgical management of ovarian
380   cancer: Prevalence and implications. Gynecologic oncology. 2016;142(1):30-7.
381   10.   Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, et al.
382   Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and
383   IV patients. European journal of surgical oncology : the journal of the European Society of Surgical
384   Oncology and the British Association of Surgical Oncology. 2009;35(2):135-43.
385   11.   Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and
386   maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
387   Gynecologic oncology. 1998;69(2):103-8.
388   12.   Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery
389   for advanced ovarian cancer: an economic analysis. Gynecologic oncology. 2009;112(1):16-21.
390   13.   Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al.
391   Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in
392   surgical paradigm. Gynecologic oncology. 2009;114(1):26-31.
393   14.   Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, et al. Prognostic
394   impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Annals
395   of surgical oncology. 2010;17(1):279-86.
396   15.   Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, et al. Role of
397   maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer:
398   Surgical and oncological outcomes. Single institution experience. Gynecologic oncology.
399   2010;119(2):259-64.
400   16.   Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and
401   morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecologic
402   oncology. 2008;109(2):303-7.
403   17.   Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al.
404   Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of
405   Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
406   Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.
407   18.   British Gynaecological Cancer Society. British Gynaecological Cancer Society (BGCS)
408   Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for
409   Practice. 2017.
410   19.   Phillips A, Pounds R, Balega J, Singh K. Histopathological correlation of splenic disease with
411   radiological and surgical findings: should we incorporate into standard procedures for disseminated
412   Mullerian adenocarcinoma? European journal of gynaecological oncology. 2016;37(5):678-84.
413   20.   Abdel-Rahman ME, Butler J, Sydes MR, Parmar MK, Gordon E, Harper P, et al. No
414   socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. British
415   journal of cancer. 2014;111(3):589-97.
416   21.   Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, et al. Prognostic impact of
417   debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
418   Gynecologic oncology. 2016;140(2):215-20.
419   22.   Bachmann C, Bachmann R, Fend F, Wallwiener D. Incidence and Impact of Lymph Node
420   Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment. Journal of Cancer.
421   2016;7(15):2241-6.
422   23.   Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy
423   followed by interval debulking surgery for patients with advanced ovarian cancer. Archives of
424   gynecology and obstetrics. 2016;293(1):163-8.

425 24.   Feng Z, Wen H, Bi R, Yang W, Wu X. Prognostic impact of the time interval from primary
426 surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic oncology.
427 2016;141(3):466-70.
428 25.   Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, et al. Patterns of Recurrence
429 and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete
430 Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy
431 Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. International
432 journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
433 2017;27(1):28-36.
434 26.   Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of
435 ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery
436 for epithelial ovarian cancers likely to have suboptimal resection. Gynecologic oncology.
437 2017;144(2):266-73.
438 27.   Heitz F, Harter P, Alesina PF, Walz MK, Lorenz D, Groeben H, et al. Pattern of and reason
439 for postoperative residual disease in patients with advanced ovarian cancer following upfront radical
440 debulking surgery. Gynecologic oncology. 2016;141(2):264-70.
441 28.   Luo Y, Lee M, Kim HS, Chung HH, Song YS. Effect of neoadjuvant chemotherapy on
442 platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine. 2016;95(36):e4797.
443 29.   Medina-Franco H, Cortes-Gonzalez R, Lambreton-Hinojosa F, Fimbres-Morales A, Vargas-
444 Siordia JC. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve
445 Final Outcome in Advanced Epithelial Ovarian Cancer. Annals of surgical oncology. 2016.
446 30.   Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant
447 chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a
448 comprehensive cancer center. Gynecologic oncology. 2016;140(3):436-42.
449 31.   Munoz-Casares FC, Medina-Fernandez FJ, Arjona-Sanchez A, Casado-Adam A, Sanchez-
450 Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal
451 carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume
452 center. European journal of surgical oncology : the journal of the European Society of Surgical
453 Oncology and the British Association of Surgical Oncology. 2016;42(2):224-33.
454 32.   Oseledchyk A, Hunold LE, Mallmann MR, Domrose CM, Abramian A, Debald M, et al.
455 Impact of Extended Primary Surgery on Suboptimally Operable Patients With Advanced Ovarian
456 Cancer. International journal of gynecological cancer : official journal of the International
457 Gynecological Cancer Society. 2016;26(5):873-83.
458 33.   Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodriguez-Tapia A, Cuesta-Guardiola
459 T, et al. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer:
460 Analysis of prognostic factors related to overall survival and progression-free survival after an
461 extended long-term follow-up period". Surgical oncology. 2016;25(1):49-59.
462 34.   Plotti F, Montera R, Aloisi A, Scaletta G, Capriglione S, Luvero D, et al. Total
463 rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian
464 cancer. European journal of surgical oncology : the journal of the European Society of Surgical
465 Oncology and the British Association of Surgical Oncology. 2016;42(3):383-90.
466 35.   Skof E, Merlo S, Pilko G, Kobal B. The role of neoadjuvant chemotherapy in patients with
467 advanced (stage IIIC) epithelial ovarian cancer. Radiology and oncology. 2016;50(3):341-6.
468 36.   Stewart JM, Tone AA, Jiang H, Bernardini MQ, Ferguson S, Laframboise S, et al. The
469 optimal time for surgery in women with serous ovarian cancer. Canadian journal of surgery Journal
470 canadien de chirurgie. 2016;59(4):223-32.
471 37.   Sun JH, Ji ZH, Yu Y, Wu HT, Huang CQ, Zhang Q, et al. Cytoreductive Surgery plus
472 Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer:
473 Results from a Retrospective Study on Prospectively Established Database. Translational oncology.
474 2016;9(2):130-8.
475 38.   Xu X. DF, Lv M., Ren B., Guo W., Chen X. Ascites regression following neoadjuvant
476 chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian
477 cancer. Journal of ovarian research. 2016;9(1):85.

478   39.   Matz M, Coleman MP, Carreira H, Salmeron D, Chirlaque MD, Allemani C, et al. Worldwide
479   comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
480   Gynecologic oncology. 2017;144(2):396-404.
481   40.   SOCQER-2. SOCQER-2 2016 [cited 2016 7th June]. Available from:
482   https://clinicaltrials.gov/ct2/show/NCT02569983.
483   41.   ESGO. Advanced (StageIII-IV) Ovarian Cancer Surgery Quality Indicators. 2016.
484   42.   Royal College of Surgeons of England (RCS). National Bowel Cancer Audit. 2015.
485   43.   Royal College of Surgeons of England (RCS). National Oesophago-Gastric Cancer Audit.
486   2016.
487   44.   COMET (Core Outcome Measures in Effectiveness Trials) Initiative.
488   45.   CROWN (Core outcomes in women's and newborn health).

489

Table 1: Clinicopathological data of the total patient cohort presented comparing patients who did not undergo surgery with those who underwent surgical management of AOC

	Non-surgical cases		Surgical cases		*p*
	n = 152		n = 441		
Age	72.3		63.27		*<0.00001*
	(95% CI 61.3 - 83.3)		(95% CI 51.46 - 75.08)		
PS (Median IQR)	2 (1-2) (54 cases)		1 (0-1) (307 cases)		*<0.00001*
ACCI	4 (3-5) (70cases)		2 (0-3) (441 cases)		*<0.00001*
LSOA Deprivation Score	3 (2-5)		5 (2-7)		*<0.00001*
Stage					
3	92	60.5%	347	78.7%	*0.000011*
4	56	36.8%	94	21.3%	*0.000146*
Unstaged advanced	4	2.6%	0	0.0%	*0.00063*
Site of origin					
Ovary	124	81.6%	322	73.0%	*0.034988*
Peritoneal	28	18.4%	78	17.7%	*>0.05*
Tubal	0	0.0%	41	9.3%	*0.000098*
Histology					
Serous	107	70.4%	348	78.9%	*0.032121*
Serous low grade	3	2.0%	23	5.2%	*>0.05*
Mucinous	2	1.3%	3	0.7%	*>0.05*
MMMT	3	2.0%	22	5.0%	*>0.05*
Mixed Epithelial	1	0.7%	15	3.4%	*>0.05*
Psammomatous	1	0.7%	0	0.0%	*>0.05*
Clear Cell	2	1.3%	16	3.6%	*>0.05*
unknown	31	20.4%	3	0.7%	*<0.00001*
Mullerian	2	1.3%	2	0.5%	*>0.05*
Undifferentiated/Anaplastic	0	0.0%	4	0.9%	*>0.05*
Endometroid	0	0.0%	5	1.1%	*>0.05*

Table 2. Impact on median OS by group of patients analysed demonstrating the 'Denominator effect'.

Treatment group	Median OS (months) (95% CI)	*p*
A: Patients undergoing PDS	54.5 (35.7 – 73.3)	0.000586
B: Group A and patients undergoing IDS	38.7 (34.9 – 42.4)	0.000353
C: Group B and patients assessed for IDS	35.4 (31.9 – 38.8)	0.039180
D: All AOC patients receiving any treatment	33.3 (29.8 – 36.8)	0.393738
E: All advanced ovarian cancer patients	30.2 (26.7 – 32.6)	Reference

4. Table

Table 3: Reporting of denominator data, surgical cohort data and survival data in included studies

Study	Journal	Stage	Total operated patients	Study group and number of patients on whom survival data is presented	OS in study group (Median OS +/-95% CI) months or 5-year survival	Denominator Data (Total patient number)	Total Cohort OS (Median +/- 95% CI) months or 5-year survival
Ataseven et al (1)	*Gynecol Oncol*	4	315	PDS:286	16 (12–20) - 50 (3–57)	355	PDS + No surgery: 30 (NACT patients excluded)
Bachmann et al (2)	*J Cancer*	3c -4	Not stated	R0/R1: 108	18.8 (9.7 – 27.9) - 30.5 (24.7 – 57.3)	Not stated	Not stated
Bian et al (3)	*Arch Gynecol Obstet*	3c -4	339	IDS: 114 PDS:225	IDS: 25 (21.7–28.3) PDS: 25 (22.1–27.9)	Not stated	Not stated
Feng et al (4)	*Gynecologic Oncology*	1 - 4	625	625	51.40%	Not stated	Not stated
Gadducci et al (5)	*Int J Gynecol Cancer*	3c-4	384	IDS: 64 PDS: 322	IDS: 41.8% PDS: 69.3%	Not stated	Not stated
Gill et al (6)	*Gynecol Oncol*	3c -4	Not stated	IDS (?R2): 45 PDS (R2): 45	IDS 28.2 PDS: 16.8	Not stated	Not stated
Heitz et al (7)	*Gynecol Oncol*	3b-4	663	PDS: 578	49 (42–55)	739	Not stated
Luo et al (8)	*Medicine*	3c-4	370	Overall: 341 PDS: 283 IDS: 58	Overall 50.0 (44.5–55.5) PDS: 51.0 IDS: 41.0	Not stated	Not stated

Medina-Franco et al (9)	*Ann Surg Oncol*	3c-4	105	Overall: 105 PDS: 42 IDS: 63	Overall: 38 PDS: 33.59 IDS: 56.4	Not stated	Not stated
Mueller et al (10)	*Gynecol Oncol*	3-4	581	581 IDS: 149 PDS: 432	Overall 63.2 (55.3–73.2) PDS 71.7(59.8-not reached) IDS (42.9 (37.1–56.3)	Not stated	Not stated
Munoz-Casares et al(11)	*Eur J Surg Oncol*	3c-4	Not stated	IDS + HIPEC: 124	49%	Not stated	Not stated
Oseledchyk et al(12)	*Int J Gynecol Cancer*	3-4	278	R1/R2: 96	19.5 - 32.9	Not stated	Not stated
Pereira et al(13)	*Surgical Oncology*	3-4	Not stated	116	If alive: 169.8 If dead: 34.9 months	Not stated	Not stated
Phillips et al		3-4	441	All surgery: 441 PDS: 140	All surgery: 38.7 (34.9-42.4). PDS: 54.5 (35.7-73.3)	593	30.2 (26.7-32.6)
Plotti et al(14)	*Eur J Surg Oncol*	3-4	337	PDS: 154	48-52%	Unclear	Not stated
Skof et al(15)	*Radiol Oncol.*	3c-4	160	PDS: 80 IDS 80	PDS: 31.6 IDS 24.8	Unclear	Not stated
Stewart et al(16)	*Can J Surg*	3-4	334	IDS: 156 PDS: 178	IDS: 33.4 PDS 69.5	Not stated	Not stated
Sun et al(17)	*Transl Oncol*	3c-4	Not stated	PDS + HIPEC: 46	74.0 (8.5-139.5)	Not stated	Not stated
Xu et al(18)	*J Ovarian Res*	3c - 4	Not stated	IDS: 160	32.1 (27.1–37.1)	Not stated	Not stated

Legend: PDS = Primary debuking surgery; IDS = Interval debulking surgery; R0= Complete cytoreduction; R1 = Optimal <1cm residual disease; R2= Suboptimal >1cm residual disease; HIPEC = Hyperthermic intraperitoneal chemotherapy

1.	Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic oncology. 2016;140(2):215-20.

2.	Bachmann C, Bachmann R, Fend F, Wallwiener D. Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment. Journal of Cancer. 2016;7(15):2241-6.

3.	Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Archives of gynecology and obstetrics. 2016;293(1):163-8.

4.	Feng Z, Wen H, Bi R, Yang W, Wu X. Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic oncology. 2016;141(3):466-70.

5.	Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, et al. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017;27(1):28-36.

6.	Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecologic oncology. 2017;144(2):266-73.

7.	Heitz F, Harter P, Alesina PF, Walz MK, Lorenz D, Groeben H, et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecologic oncology. 2016;141(2):264-70.

8.	Luo Y, Lee M, Kim HS, Chung HH, Song YS. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine. 2016;95(36):e4797.

9.	Medina-Franco H, Cortes-Gonzalez R, Lambreton-Hinojosa F, Fimbres-Morales A, Vargas-Siordia JC. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Annals of surgical oncology. 2016.

10.	Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic oncology. 2016;140(3):436-42.

11.	Munoz-Casares FC, Medina-Fernandez FJ, Arjona-Sanchez A, Casado-Adam A, Sanchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(2):224-33.

12.	Oseledchyk A, Hunold LE, Mallmann MR, Domrose CM, Abramian A, Debald M, et al. Impact of Extended Primary Surgery on Suboptimally Operable Patients With Advanced Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016;26(5):873-83.

13.	Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodriguez-Tapia A, Cuesta-Guardiola T, et al. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period". Surgical oncology. 2016;25(1):49-59.

14. Plotti F, Montera R, Aloisi A, Scaletta G, Capriglione S, Luvero D, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(3):383-90.

15. Skof E, Merlo S, Pilko G, Kobal B. The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiology and oncology. 2016;50(3):341-6.

16. Stewart JM, Tone AA, Jiang H, Bernardini MQ, Ferguson S, Laframboise S, et al. The optimal time for surgery in women with serous ovarian cancer. Canadian journal of surgery Journal canadien de chirurgie. 2016;59(4):223-32.

17. Sun JH, Ji ZH, Yu Y, Wu HT, Huang CQ, Zhang Q, et al. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database. Translational oncology. 2016;9(2):130-8.

18. Xu X. DF, Lv M., Ren B., Guo W., Chen X. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Journal of ovarian research. 2016;9(1):85.

Figure 1: Flowchart demonstrating patient outcomes for the total patient cohort "denominator"

```
                    ┌─────────────────────────┐
                    │   Total patient Cohort   │
                    │      "denominator"       │
                    │         n=593            │
                    └─────────────────────────┘
```

Group E

No surgery: No data available n =3 (0.5%)
Died during initial diagnostic period n=1 (0.2%)

DIAGNOSIS AND INITIAL MDT DISCUSSION WITH RESULTS OF INITIAL
IMAGING, TUMOUR MARKERS AND PATIENT ASSESSMENT
n=589 (99.3%)

Palliation of symptoms only:
No chemotherapy or cytoreductive surgery
n=25 (4.2%)

Group D

Intention to treat with NACT
n=418 (70.5%)

Patient refusal of chemotherapy
n=5 (0.8%)
Died prior to commencing chemotherapy
n=14 (2.5%)
Died during NACT
n=12 (2.0%)
NACT not tolerated (Discontinued)
n=1 (0.2%)

Group C

SECONDARY MDT DISUSSION WITH REVIEW OF IMAGING,
TUMOUR MARKERS AND PATIENT ASSESSMENT
n= 386 (65.1%)

Patient refusal of IDS
n=7 (1.2%)
Progressive disease
n =24 (4.0%)
Extra abdominal disease
n = 3 (0.5%)
Stable disease
n = 21 (3.6%)
Irresectable disease
n=3 (0.5%)
No disease to resect
n=1 (0.2%)
Not fit for surgery
n=30 (5.1%)
Died prior to surgery
n=1 (0.2%)
No surgery – reason unknown
n=1 (0.2%)

Group B

Group A:
Primary Debulking Surgery
n=146 (24.6%)

Interval debulking surgery
N=295 (49.7%)

Figure 2: Kaplan-Meier curve comparing OS by patient groups A-E.

Highlights

- Survival from AOC is influenced by the total patient cohort 'denominator'

- Literature on outcomes after surgery contain denominator descriptors infrequently

- Denominator data is essential for benchmarking in gynaeoncology

- Denominator data should be described in surgical studies